Compare Enovix Corporation (ENVX) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Incyte Corporation — how do they compare? Enovix Corporation trades at $2.45 (market cap $549.72M), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 41.6× Enovix Corporation's market cap, and Incyte Corporation is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Incyte Corporation for 33 Days on average.
| ENVX | INCY | |
|---|---|---|
Market Cap | $549.72M | $22.85B |
Volume | 6,635,687 | 1,927,029 |
Sector | Industrials | Health |
52-Week High | $13.19 | $129.93 |
52-Week Low | $2.50 | $83.80 |
Typical Hold Time | 11 Days | 33 Days |
Enterprise Value | $611.42M | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.485, down 2.55% on the day, reflecting a bearish technical outlook. The company continues to post significant losses, with a net income margin of -473.89% in 2026, though quarterly earnings have consistently beaten expectations. Recent news is dominated by a sudden CEO transition, but the company reaffirmed its strategy and guidance, highlighting progress in its drone and defense battery supply chain.
The outlook is highly speculative. Analyst consensus is bullish with a $10.75 price target, but substantial execution risks and persistent cash burn pose a threat to shareholder value. Investment potential hinges on successful commercialization and achieving profitability, which remains distant.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
